Short answer: patches are the least evidenced of the three. NAD+ is a large, water-soluble, negatively charged molecule — close to the worst possible profile for crossing intact skin. IV bypasses that problem entirely but is expensive and short-lived. Oral precursors are the only route with a developed human trial record. If you are choosing between the three on evidence rather than convenience, the order is not the one the marketing suggests.
Why transdermal is hard for this specific molecule
The outer layer of skin, the stratum corneum, is a lipid barrier. Molecules that cross it passively tend to share a profile: small — generally under about 500 daltons — and lipophilic enough to dissolve into that lipid layer.
NAD+ fails on both counts. Its molecular weight is roughly 663 daltons, above the usual rule-of-thumb ceiling, and it carries negative charge at physiological pH, which makes partitioning into a lipid barrier unfavourable. This is basic pharmaceutics rather than a controversial position, and it is why transdermal drug delivery is dominated by small lipophilic molecules such as nicotine, fentanyl and hormones.
None of that makes a patch impossible — formulation science exists precisely to solve such problems, using permeation enhancers, microneedles or iontophoresis. But a patch making that claim should be able to show the delivery data, and consumer NAD+ patches generally do not.
What to ask a patch manufacturer
One question separates a real transdermal product from a sticker: what proportion of the labelled dose is absorbed, and what measurement supports that figure?
A genuine transdermal product has a flux measurement — how much crosses skin per square centimetre per hour — and usually a pharmacokinetic study showing blood levels over time. If the answer is a testimonial, an "energy" claim, or a milligram figure printed on the patch with no absorption data behind it, the milligram figure is the amount in the adhesive, not the amount that reaches you.
How the three routes compare
IV. Delivers the finished molecule directly to plasma. Highest acute blood levels by a wide margin. Also the most expensive, the most time-consuming, and the least supported by controlled trials in healthy adults. The rise clears within hours. Covered in full in NAD+ Injections vs Oral NMN.
Patch. Convenient, and that is the honest sum of its established advantages. The barrier physics are unfavourable and the published human absorption data for NAD+ patches specifically is essentially absent.
Oral precursor. Does not deliver NAD+ itself — it delivers NMN or NR (Nicotinamide riboside), which cells convert internally via the salvage pathway. Trammell and colleagues (2016) showed oral NR raises human blood NAD+ dose-dependently, and Martens and colleagues (2018) confirmed chronic supplementation stimulates NAD+ metabolism in middle-aged and older adults. Yoshino and colleagues (2021) reported a functional outcome from oral NMN.
Why "bypasses first-pass metabolism" is the wrong argument
The standard patch pitch is that swallowing a supplement subjects it to first-pass liver metabolism, whereas a patch avoids it. That is true as a general principle of pharmacology, and irrelevant here.
Oral NMN is not trying to survive intact to the bloodstream as NAD+. It is a precursor. Conversion is the mechanism, not a loss. Framing hepatic metabolism as waste misdescribes how the salvage pathway works — and the human data showing that oral dosing does in fact raise NAD+ settles the point empirically regardless of the theory.
What we would actually do
Take the route with trial data, take it daily, and give it the eight to twelve weeks the studies used before judging it. That means an oral precursor: NMN at 500 mg per capsule, or NAD+ Full Stack with quercetin and resveratrol, or both as the Longevity Stack.
If you want to explore IV, do it with a clinician and clear expectations. If you want to try a patch, ask for the flux data first — and treat the absence of an answer as the answer.
Frequently Asked Questions
Quick answers to the questions readers most often ask.
Do NAD+ patches work?
There is very little published human absorption data for NAD+ patches. The molecule is roughly 663 daltons and carries negative charge at physiological pH, which is an unfavourable profile for crossing the skin's lipid barrier — transdermal delivery generally favours small lipophilic molecules. A patch claiming otherwise should be able to provide flux or pharmacokinetic data.
Is an NAD+ patch better than a capsule?
On published evidence, no. Oral precursors such as NMN and nicotinamide riboside have human trials showing dose-dependent NAD+ elevation and, in one case, a functional metabolic outcome. Consumer NAD+ patches generally have no comparable absorption data.
What is the difference between an NAD+ patch and an NAD+ IV?
An IV delivers the finished molecule directly into the bloodstream, producing high but short-lived plasma levels. A patch relies on the molecule crossing intact skin, which is pharmaceutically difficult for a large charged compound. The IV route works mechanically; the patch route is unproven for this molecule.
Does oral NMN get destroyed by the liver?
This misdescribes the mechanism. NMN is a precursor, not the finished coenzyme — cells convert it to NAD+ through the salvage pathway, so metabolism is the intended route rather than a loss. Human trials confirm oral dosing raises NAD+ regardless of the theoretical objection.
How much of the labelled dose on a patch actually gets delivered?
Without a flux measurement or a pharmacokinetic study, the milligram figure on a patch describes the amount loaded into the adhesive, not the amount absorbed. Those are very different numbers, and only the second one matters.
References
- Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016.
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
